better-than-expected executed for our Endo business the relentless progress in in all quarter morning, Qwo this results, our for milestone transforming to everyone, an Thank of long-term deliver I’m quarter maintained of focus We March, all the our and us continue you, joining parts team priorities, to our across strategic important the of value make delivered business. morning. way launch our Laure, and on thank first proud against of achievement good you including our this with of stakeholders. and order
review the recognize work. the of of where and for parts of vaccines To our are world, working to to of including ongoing members, our support quarter, of needed. safety and I India, safety provide expanded team in the protocols moving many live our and continued in team the many if treatment Before further COVID-XX services provide to members challenges want services we’ve and
Additionally, our pandemic COVID-XX in affected strategic our the the start we pipeline Mark by of are On Indian expectations priorities, members, have discussion to quarter our to Slide our behalf the an in updates a to will I will business to If Cross. express I first with India. for first our agenda X, our financial provide financial on on results performance our making then those quarter and donations who deepest India, address and efforts XXXX. move to assist by the we on followed sympathies been update including release Red donations of with Endo team want ongoing
Turning X. to Slide
around Report, do that live value all this of creating help and stakeholders three best is benefits good foundation all to environmental, transform our progress we sustainable Being guide to one people as as force week, and Corporate which and we for company. priorities our our serves our performance strategy an to annual priorities and governance Earlier strategic Our our that adapt sustainable which practices their accounting Responsibility life. published the social is XXXX our more we of is of a work our built.
in in have front, progress I’m date this pleased with as to our early reflected journey much to While our latest on and we are ESG do report. our
snapshot a our is EBITDA Slide revenues, of for and to our X. consolidated the segment This adjusted quarter. and Moving
to adjusted decreased prior lower Generic higher first of consolidated to launch million decrease quarter compared of XIAFLEX. This our by of year. prior to segment decreased due was to coupled decrease investment expenses, commercial was revenues. primarily the XX% operating EBITDA our primarily year. This revenue First adjusted Reported XX% Qwo $XXX in Pharmaceuticals strong $XXX quarter compared and continued due lower with investment anticipated and revenues reflecting million revenues in Sterile Injectable
to certain XXXX higher adjusted revenues products exceeded due expenses and to across operating key communicated our product margin better-than-expected consolidated mix quarter due EBITDA and gross partly in First previously our adjusted adjusted lower to mainly phasing. favorable expectations segments, performance due
Slide to Turning X.
XXXX to segment channel first growth demand specialty Branded increased prior products first the year. year, quarter of compared Our X%. to growth driven by in strong of first X% driven XIAFLEX revenues by inventory the quarter XIAFLEX revenue compared compared to year, revenues by offset by the prior both quarter in that prior indications, increased occurred partially for portfolio destocking
options year, we’re in XIAFLEX strategy expanded that awareness education increasing patients nonsurgical earlier empower this discussed investing physician with to training. we and As the coupled to seek includes through patient commercial promotion
line We’re is seek encouraged our treatment, indications and sites. locator traffic demand by good both consumer the physician measured as strong fueling a website underlying across to This which patient is by interest to pre-COVID the visits consumer fairly quarter levels elective to be office early first our we’re indicator initial for of below patient activation. in procedures in with and expectations. interest Patient and continued
Injectables half the portfolio visits increase on levels this, procedures first weighted in by same period XXXX. our the to toward patient was of the as over by the certain competitive office ertapenem compared Revenues the to of March, of of impact second revenue physician-administered than declined due of generic X% our declined the quarter more year, to nationally in offset by our continue the primarily the of prior such from year. Based ongoing for for of Revenues products, quarter quarter we growth X% segment year. the revenue expect competition. the to specifically adrenaline to utilization encouraged XX% Products by to Established higher vaccinations than products pressures. Sterile due and first from steadily decrease XIAFLEX such utilization, elective as increasing and VASOSTRICT month remainder we expected. be in expect compared VASOSTRICT in was to of the We’re the
look However, that we forward, decreased to hospitalizations quarter as VASOSTRICT of COVID-XX-related continue as volumes during we second expect levels the begin pre-COVID-XX to decline. to XXXX, toward
to Generic COVID-XX to occurred our that impact products, accelerated prescription decrease certain decreased Slide on first coupled This capsules, to by first primarily quarter to decline year. quarter X. competition the key of XX% delayed impact Revenues expectations the pressures The XXXX. by partially generic with the segment Moving exceeded to compared our generic was prior in on quarter primarily from of the lubiprostone launch revenues segments in of with the first for anticipated successful was the higher-than-expected launch coupled of due offset competitive in of January the certain authorized due anticipated this year. the fulfillment related performance, products. lubiprostone Generic Amitiza,
expected ongoing decrease in International segment for generic the due was Finally, revenues to quarter the competition. first primarily
Turning to Slide X.
early the grow practitioners Qwo in managing cause that new product vertical building first targeted Medical select program an into program and opportunity our selection, launch only The approved their business. focused on practice patient a treatment Medical to Aesthetics unique profile an education, expectations, launched and We through the and that experience practices. provides patient success. and cellulite. create by underlying option for Aesthetics We of Qwo addresses nonsurgical of entry the excited a Qwo the cellulite, provides March. Qwo’s the with of the is are injectable We believe
of we Qwo, As are are year, a discussed progressive earlier undertaking the our and process we and this in for boarding deliberate activating to we launch on taking approach accounts.
Ongoing began of being early additional with delivered Activated onboarding month the after educational April, and process accounts supported rollout webinars During will we program, delivered be strong the of important a the both peer-to-peer training virtually education will through programming. and of are to in be our and continue virtual injector accounts. program, successful person. experience
equip have course. support accomplish activation. We health tools to practice the our goal, need Qwo professional practices they also to need recognized launched we integration with To this the
pricing received announced community. feedback strong Qwo buzz pictures strong and of proposition by treatment. generated on for our availability after the practices announcing social seeking and Activated and media. Aesthetic represents Medical believe the we point practices for price Qwo positive who launch are have before on To have Additionally, we and consumers posting value own a date, their
first consumer excitement than trade, interest and remains to XXX,XXX and top media Additionally, broadcast in outlets. print including webpage, visitors unique tier quarter impressions and media strong, Cellulite more the the X.X billion than with and greater Really
we our target about on and on only account are month rates. one boarding, post planned While purchase launch, utilization with
progress, becomes we more we it will As more information share as meaningful.
discussing clinical and Moving studies pipeline. segment and Starting Qwo. ongoing our to Branded with X Slide
on as dosing, on focused populations, remains development responses durability. and target well technique plan generation studies patient as in data Our injection and rollover
real incorporate example, greater our or as population practice. real thigh XX, than Results experience. XXX and key of at into are study world well appearance publication to studies in XX% Qwo scores these Xb investigator XX% agreed day analysis cellulite a presentation investigators looked strongly their improvement were and and agreed from strategies. to and as investigator our At injection overall For Phase perceived technique effectiveness Qwo in
with progress We coming publication in plan make of initiation the study looking of study our are treatment a XIAFLEX of X this the of to fibromatosis proof-of-concept continue fibromatosis, of Starting the plantar our the our year. second with We in to program plantar on date progress half we to programs. forward Phase development results the months.
believe terms represent analysis nonsurgical treatment the unmet capsulitis to patients end We address year. a large for Xb Phase potential and to adhesive need both capsulitis, are opportunity of to a treatment. toward anticipated our seeking who the fibromatosis bring plantar In innovative is adhesive approach of option an interim study
X. Slide Turning to
XX% and to pipeline on continue support launch use the and approximately quarter continuum, two successful to of of products evolving Injectables sterile plan introduction the other which across the We focusing of Sterile thirds of generic the R&D XXXX, lubiprostone and Injectable our our Amitiza, customers. R&D evolve ready XX And capabilities with of the our differentiated the we segments, products, Sterile with projects includes product products. approximately this first in pipeline capsules, more authorized consists to of needs year. of in to in more Generic launch Across manufacturing
to turn over discuss call to our me Mark? results guidance. and financial company’s Mark let further financial the Now, the
